Stifel analyst Annabel Samimy initiated Revance (RVNC) with a Buy rating and $50 price target, citing her view that the company’s daxibotulinumtoxinA represents “one of the first truly novel neurotoxin formulations” and potentially offers six-month duration of effect as compared to the 3-4 months for Allergan’s (AGN) Botox and competitors’ agents.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.